The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology
Open accessAbstract
We have generated a novel transgenic mouse model on a C57BL/6J genetic background that coexpresses KM670/671NL mutated amyloid precursor protein and L166P mutated presenilin 1 under the control of a neuron-specific Thy1 promoter element (APPPS1 mice). Cerebral amyloidosis starts at 6-8 weeks and the ratio of human amyloid (A)beta42 to Abeta40 is 1.5 and 5 in pre-depositing and amyloid-depositing mice, respectively. Consistent with this ratio, extensive congophilic parenchymal amyloid but minimal amyloid angiopathy is observed. Amyloid-associated pathologies include dystrophic synaptic boutons, hyperphosphorylated tau-positive neuritic structures and robust gliosis, with neocortical microglia number increasing threefold from 1 to 8 months of age. Global neocortical neuron loss is not apparent up to 8 months of age, but local neuron loss in the dentate gyrus is observed. Because of the early onset of amyloid lesions, the defined genetic background of the model and the facile breeding characteristics, APPPS1 mice are well suited for studying therapeutic strategies and the pathomechanism of amyloidosis by cross-breeding to other genetically engineered mouse models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Activated microglia surround amyloid plaques in the brains of both human patients with AD and mouse models of Aβ amyloidosis13,15,21,22.”
From Deletion of SPI1 in microglia exacerbates amyloid pathology by impairing microglial response in Alzheimer’s disease models (2026) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although a previous report demonstrated no sex-dependent differences in Aβ accumulation in this APPPS1–21 mouse model13”
From Deletion of SPI1 in microglia exacerbates amyloid pathology by impairing microglial response in Alzheimer’s disease models (2026) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A previous report demonstrated no sex-dependent difference in the phenotypes of APP(Swe)/PS1(L166P) mice8.”
From Effects of SPI1-mediated transcriptome remodeling on Alzheimer's disease-related phenotypes in mouse models of Aβ amyloidosis (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The reactive gliosis, encompassing microgliosis and astrogliosis, are prevalent neuropathological hallmarks observed in the brains of both human AD and mouse models of Aβ amyloidosis8,15,16.”
From Effects of SPI1-mediated transcriptome remodeling on Alzheimer's disease-related phenotypes in mouse models of Aβ amyloidosis (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because it has been known that there is no sex effect in this experimental group8, male and female mice were combined for statistical analyses.”
From Effects of SPI1-mediated transcriptome remodeling on Alzheimer's disease-related phenotypes in mouse models of Aβ amyloidosis (2024) · cites this paper as [8]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sample sizes were chosen based on prior publications using the APP/PS1 and P301S mouse models, which provided estimations of expected effect sizes and variance.”
From APOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints (2023) · cites this paper as Radde et al., 2006
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The APPPS1-21 (APPPS1) mouse line coexpresses human amyloid precursor protein harboring the K670M/ N671L familial AD mutation and presenilin 1 harboring the L166P familial AD mutation, under the control of the neuron-specific Thy1 promoter.21”
From CX3CR1 Deficiency Alters Microglial Activation and Reduces Beta-Amyloid Deposition in Two Alzheimer's Disease Mouse Models (2010) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APPPS1 mouse line coexpresses APP K670M/N671L and PS1 L166P mutations under the control of the neuronspecific Thy1 promoter and exhibits early and robust A deposition beginning at 6 -8 weeks of age in the cortex and 3-4 months of age in the hippocampus.21”
From CX3CR1 Deficiency Alters Microglial Activation and Reduces Beta-Amyloid Deposition in Two Alzheimer's Disease Mouse Models (2010) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“dozens of mouse lines overexpressing several combinations of APP and PSEN1 mutations have been created to accelerate the onset of Aβ pathologies in brains [28–30].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [30]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The APPPS1–21 mouse model used in our study starts to accumulate Aβ in the neocortex at approximately 6 to 8 weeks of age and exhibits robust Aβ accumulation and plaque deposition at 4 months of age13.”
From Deletion of SPI1 in microglia exacerbates amyloid pathology by impairing microglial response in Alzheimer’s disease models (2026) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“Abnormal activation of microglia and astrocytes is observed in the brains of AD patients15 and APPPS1–21 transgenic model mice13.”
From Deletion of SPI1 in microglia exacerbates amyloid pathology by impairing microglial response in Alzheimer’s disease models (2026) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“Amyloid-associated gliosis is consistently observed in the brains of AD patients15 and amyloidosis mouse models8,16.”
From Effects of SPI1-mediated transcriptome remodeling on Alzheimer's disease-related phenotypes in mouse models of Aβ amyloidosis (2024) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“APPPS1-21 mice overexpress a human APP with a Swedish mutation (KM670/671NL) and mutant PS1 with the L166P mutation.”
From Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis (2011) · cites this paper as Radde et al., 2006
The cited source says what the claim attributes to it.
In the citing paper
“During submission of this manuscript, another study (Takalo et al. 2025), using the APP/PS1 model which develops an elevated Aβ42:40 (~5:1) (Radde et al. 2006), proposed that the protective variant reduced the number of plaques and overall plaque load”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Radde et al. 2006
The cited source says what the claim attributes to it.
In the citing paper
“we mated Cx3cr1 knockout mice to two different mouse models of AD that exhibit either rapid deposition of primarily A42 (the APPPS1 model) 21 or gradual deposition of primarily A40 (the R1.40 model).[22][23][24]”
From CX3CR1 Deficiency Alters Microglial Activation and Reduces Beta-Amyloid Deposition in Two Alzheimer's Disease Mouse Models (2010) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“The increased levels of CH25H mRNA and protein were also observed in the frontal cortex of 4-month-old APPPS1-21 mice bearing amyloid plaques [65] (Fig. 1c, d, e).”
From 25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner (2020) · cites this paper as [65]
In the citing paper
“the study utilized APP/PS1 and APP23 transgenic mouse models, both of which were generated through expression of mutated PS1 and/or APP under the neuron-specific Thy1 promoter element [151, 152].”
From Microglial dysfunction in brain aging and Alzheimer's disease (2014) · cites this paper as [151]
In the citing paper
“The other major limitation of these mouse models was that while some showed evidence of localized hyperphosphylated tau that may represent “pretangles”[107, 118, 151, 159], none developed neurofibrillary tangles.”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [118]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507
Self-citationHolcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386
Borchelt, D. R., Ratovitski, T., van Lare, J., Lee, M. K., Gonzales, V., Jenkins, N. A., Copeland, N. G., Price, D. L., & Sisodia, S. S. (1997) · Neuron · doi:10.1016/s0896-6273(00)80974-5 · Cited by 1,023
Alzheimer's Disease: Molecular Understanding Predicts Amyloid-Based Therapeutics
Selkoe, D. J., & Schenk, D. (2003) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140248 · Cited by 829
IRIZARRY, M. C., MCNAMARA, M., FEDORCHAK, K., HSIAO, K., & HYMAN, B. T. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199709000-00002 · Cited by 649
Microglial response to amyloid plaques in APPsw transgenic mice.
Frautschy, S. A., Yang, F., Irrizarry, M., Hyman, B. T., Saido, T. C., Hsiao, K., & Cole, G. M. (1998) · Europe PMC (PubMed Central) · Cited by 592
Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice
McGowan, E., Pickford, F., Kim, J., Onstead, L., Eriksen, J., Yu, C., Skipper, L., Murphy, M. P., Beard, J., Das, P., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.06.030 · Cited by 565
Quantitative and qualitative analyses of clock drawings in Alzheimer's and Huntington's disease
Rouleau, I., Salmon, D. P., Butters, N., Kennedy, C. M., & McGuire, K. (1992) · Brain and Cognition · doi:10.1016/0278-2626(92)90112-y · Cited by 556
Neuron loss in APP transgenic mice
Calhoun, M. E., Wiederhold, K.-H., Abramowski, D., Phinney, A. L., Probst, A., Sturchler-Pierrat, C., Staufenbiel, M., Sommer, B., & Jucker, M. (1998) · Nature · doi:10.1038/27351 · Cited by 502
Self-citation
Flagged first, then by citations
1 of the 32 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 501–600 of 1,000
Zoufal, V., Mairinger, S., Krohn, M., Wanek, T., Filip, T., Sauberer, M., Stanek, J., Kuntner, C., Pahnke, J., & Langer, O. (2019) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19854541 · Cited by 26
Vitale, P., Pereira, A. R. S., Lupaşcu, C. A., Willem, M., Migliore, R., Migliore, M., & Marie, H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.668948 · Cited by 26
Song, H., Liu, J., Wang, L., Hu, X., Li, J., Zhu, L., Pang, R., & Zhang, A. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1348844 · Cited by 26
Bigot, C., Vanhoutte, G., Verhoye, M., & der Linden, A. V. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.10.056 · Cited by 26
Age dependency of cerebral P-glycoprotein function in wild-type and APPPS1 mice measured with PET
Zoufal, V., Wanek, T., Krohn, M., Mairinger, S., Filip, T., Sauberer, M., Stanek, J., Pekar, T., Bauer, M., Pahnke, J., et al. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x18806640 · Cited by 26
Tambini, M. D., & D'adamio, L. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.012542 · Cited by 26
Alzheimer's Disease: Many Failed Trials, So Where Do We Go from Here?
Reiss, A. B., Glass, A. D., Wısnıewskı, T., Wolozin, B. L., Gomolin, I. H., Pinkhasov, A., Leon, J. D., & Stecker, M. M. (2020) · Journal of Investigative Medicine · doi:10.1136/jim-2020-001297 · Cited by 26
Falkenhain, K., Ruiz‐Uribe, N. E., Haft‐Javaherian, M., Ali, M. A., contributors, S. C., Michelucci, P. E., Schaffer, C. B., & Bracko, O. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235691 · Cited by 25
Möhle, L., Bascuñana, P., Brackhan, M., & Pahnke, J. (2021) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2021.109371 · Cited by 25
Estrogenic hormones receptors in Alzheimer’s disease
Tecalco-Cruz, Á. C., Zepeda–Cervantes, J., & Ortega-Domínguez, B. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06792-1 · Cited by 25
Li, X., Huang, L., Kong, L., Su, Y., Zhou, H., Ji, P., Sun, R., Wang, C., Li, W., & Li, W. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12893 · Cited by 25
Deleye, S., Waldron, A., Verhaeghe, J. A. J., Bottelbergs, A., Wyffels, L., Broeck, B. V., Langlois, X., Schmidt, M. E., Stroobants, S. G., & Staelens, S. G. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.187625 · Cited by 25
Keller, T., Lopez‐Picon, F. R., Krzyczmonik, A., Forsback, S. J., Helin, J. S., Rajander, J., Teperi, S., Dollé, F., Rinne, J. O., Haaparanta‐Solin, M., et al. (2019) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19853117 · Cited by 25
Xiong, M., Roshanbin, S., Rokka, J., Schlein, E., Ingelsson, M., Sehlin, D., Eriksson, J., & Syvänen, S. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118302 · Cited by 24
Abdulhameed, N., Babin, A., Hansen, K. M., Weaver, R. R., Banks, W. A., Talbot, K., & Rhea, E. M. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01537-1 · Cited by 25
Microtubule function and dysfunction in the nervous system
Jang, E., Choi, H., & Hur, E. (2024) · Molecules and Cells · doi:10.1016/j.mocell.2024.100111 · Cited by 24
Ahmad, S. S., Khan, S. M., Kamal, M. A., & Wasi, U. (2019) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527318666191011145941 · Cited by 24
Lloyd, G. M., Trejo‐Lopez, J. A., Xia, Y., McFarland, K. N., Lincoln, S., Ertekin‐Taner, N., Giasson, B. I., Yachnis, A. T., & Prokop, S. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-0891-3 · Cited by 24
Qin, T., Prins, S., Groeneveld, G. J., van Westen, G. J. P., de Vries, H. E., Wong, Y. C., Bischoff, L. J. M., & de Lange, E. C. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093158 · Cited by 24
The emerging role of the microbiome in Alzheimer's disease
Wasén, C., Simonsen, E., Ekwudo, M. N., Profant, M. R., & Cox, L. M. (2022) · International review of neurobiology · doi:10.1016/bs.irn.2022.09.001 · Cited by 24
High throughput object-based image analysis of β-amyloid plaques in human and transgenic mouse brain
Samaroo, H., Opsahl, A., Schreiber, J., O'Neill, S., Marconi, M., Qian, J., Carvajal‐Gonzalez, S., Tate, B. A., Milici, A. J., Bales, K. R., et al. (2011) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2011.10.003 · Cited by 24
Li, K., Gong, P., Li, J., Xu, N., & Qin, S. (2020) · Glia · doi:10.1002/glia.23845 · Cited by 24
van der Spek, S. J. F., Gonzalez‐Lozano, M. A., Koopmans, F., Miedema, S. S. M., Paliukhovich, I., Smit, A. B., & Li, K. W. (2021) · Cells · doi:10.3390/cells10071588 · Cited by 24
Extolling the benefits of molecular therapeutic lipidation
Avadisian, M., & Gunning, P. T. (2013) · Molecular BioSystems · doi:10.1039/c3mb70147f · Cited by 24
Disrupted cross-laminar cortical processing in β amyloid pathology precedes cell death
Lison, H., Happel, M. F. K., Schneider, F., Baldauf, K., Kerbstat, S., Seelbinder, B., Schneeberg, J., Zappe, M., Goldschmidt, J., Budinger, E., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.11.014 · Cited by 23
Son, H. J., Jeong, Y. J., Yoon, H. J., Lee, S. Y., Choi, G.-E., Park, J. A., Kim, M. H., Lee, K. C., Lee, Y. J., Kim, M. K., et al. (2018) · BMC Neuroscience · doi:10.1186/s12868-018-0447-7 · Cited by 23
Kelliny, S., Lin, L., Deng, I. B., Xiong, J., Zhou, F. H., Al‐Hawwas, M., Bobrovskaya, L., & Zhou, X. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02338-5 · Cited by 23
del Campo, M., & Teunissen, C. E. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131364 · Cited by 23
Bascuñana, P., Brackhan, M., & Pahnke, J. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-201120 · Cited by 23
Dulewicz, M., Kulczyńska-Przybik, A., Słowik, A., Borawska, R., & Mroczko, B. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194575 · Cited by 22
Lin, J. E., Yuan, Y., Huang, C., Zi, J., Li, L., Liu, J., Wu, X., Li, W., Zhao, Q. H., Li, Y., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107929 · Cited by 22
Santos‐García, I., Bascuñana, P., Brackhan, M., Villa, M. P., Eiriz, I., Brüning, T., & Pahnke, J. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01673-2 · Cited by 22
Kiss, É., Kins, S., Zöller, Y., Schilling, S., Gorgas, K., Groß, D., Schlicksupp, A., Rosner, R., Kirsch, J., & Kuhse, J. (2021) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2021.103624 · Cited by 22
Barendrecht, S., Schreurs, A., Geißler, S., Sabanov, V., Ilse, V., Rieckmann, V., Eichentopf, R., Künemund, A., Hietel, B., Wussow, S., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01144-y · Cited by 25
Altered dynamics of glymphatic flow in a mature-onset Tet-off APP mouse model of amyloidosis
Ben-Nejma, I. R. H., Keliris, A., Vanreusel, V., Ponsaerts, P., der Linden, A. V., & Keliris, G. A. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01175-z · Cited by 24
Kislinger, G., Niemann, C., Rodriguez, L., Jiang, H., Fard, M. K., Snaidero, N., Schumacher, A.-M., Kerschensteiner, M., Misgeld, T., & Schifferer, M. (2023) · Methods in cell biology · doi:10.1016/bs.mcb.2023.01.012 · Cited by 22
Leßmann, V., Kartalou, G.-I., Endres, T., Pawlitzki, M., & Gottmann, K. (2023) · Journal of Neural Transmission · doi:10.1007/s00702-023-02618-5 · Cited by 22
Connections between ApoE, sleep, and Aβ and tau pathologies in Alzheimer’s disease
Sadleir, K. R., & Vassar, R. J. (2023) · Journal of Clinical Investigation · doi:10.1172/jci171838 · Cited by 22
Cai, H., Wang, Y., He, J., Cai, T., Wu, J., Fang, J., Zhang, R., Guo, Z., Guan, L., Zhan, Q., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21515 · Cited by 22
Zhang, L., Tang, W. X., Chao, F., Zhou, C., Jiang, L. H., Zhang, Y., Liang, X., Tang, J., Qi, Y., Yang, H., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104723 · Cited by 22
Signatures of glial activity can be detected in the CSF proteome
Eninger, T., Müller, S. A., Bacioglu, M., Schweighauser, M., Lambert, M., Maia, L. F., Neher, J. J., Hornfeck, S. M., Obermüller, U., Kleinberger, G., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2119804119 · Cited by 24
Self-citationDimethyl fumarate does not mitigate cognitive decline and β-amyloidosis in female APPPS1 mice
Möhle, L., Brackhan, M., Bascuñana, P., & Pahnke, J. (2021) · Brain Research · doi:10.1016/j.brainres.2021.147579 · Cited by 21
Loss of CLN3 in microglia leads to impaired lipid metabolism and myelin turnover
Yaşa, S., Butz, E. S., Colombo, A. V., Chandrachud, U., Montore, L., Tschirner, S. K., Prestel, M., Sheridan, S. D., Müller, S. A., Groh, J., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-07057-w · Cited by 21
Navigating Alzheimer’s Disease Mouse Models: Age-Related Pathology and Cognitive Deficits
Plano, L. M. D., Saitta, A., Oddo, S., & Caccamo, A. (2024) · Biomolecules · doi:10.3390/biom14111405 · Cited by 22
Fuchsberger, T., Yuste, R., Martínez‐Bellver, S., Blanco-Gandia, M.-C., Torres-Cuevas, I., Blasco‐Serra, A., Arango, R., Miñarro, J., Rodríguez‐Arias, M., Teruel‐Martí, V., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190274 · Cited by 21
Essex, A. L., Huot, J. R., Deosthale, P. J., Wagner, A., Figueras, J. H., Davis, A., Damrath, J. G., Pin, F., Wallace, J. M., Bonetto, A., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4572 · Cited by 20
Transgenic Mouse Models for the Study of Neurodegenerative Diseases
Marín‐Moreno, A., Canoyra, S., Fernández‐Borges, N., Espinosa, J. C., & Torres, J. M. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2801021 · Cited by 21
Saha, P., Weigle, I. Q., Slimmon, N., Poli, P. B., Patel, P. A., Zhang, X., Cao, Y., Michalkiewicz, J., Gomm, A., Zhang, C. M., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-52246-6 · Cited by 21
Poxleitner, M., Hoffmann, S. H. L., Berezhnoy, G., Ionescu, T. M., González-Menéndez, I., Maier, F. C., Seyfried, D., Ehrlichmann, W., Quintanilla‐Martínez, L., Schmid, A. M., et al. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03080-0 · Cited by 22
Alzheimer’s Disease, Sleep Disordered Breathing, and Microglia: Puzzling out a Common Link
Ulland, T. K., Ewald, A. C., Knutson, A. O., Marino, K. M., Smith, S. M. C., & Watters, J. J. (2021) · Cells · doi:10.3390/cells10112907 · Cited by 21
Wang, J., Cheng, X., Zhang, X., Wang, T.-X., Xu, W., Li, F., Liu, F., Cheng, J., Bo, X., Wang, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8453 · Cited by 21
Astrocyte-Synapse Structural Plasticity in Neurodegenerative and Neuropsychiatric Diseases
Badia‐Soteras, A., Mak, A., Blok, T. M., Boers-Escuder, C., van den Oever, M. C., Min, R., Smit, A. B., & Verheijen, M. H. G. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2025.04.011 · Cited by 21
Screening of Alzheimer’s Disease With Multiwavelength Stokes Polarimetry in a Mouse Model
Borovkova, M. A., Sieryi, O., Lopushenko, I. V., Kartashkina, N. L., Pahnke, J., Bykov, A. V., & Meglinski, I. V. (2021) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2021.3129700 · Cited by 20
Orzyłowska, A., & Oakden, W. (2021) · Brain Sciences · doi:10.3390/brainsci12010053 · Cited by 20
Lack of N-glycosylation increases amyloidogenic processing of the amyloid precursor protein
Lin, T., van Husen, L. S., Yu, Y., Tjernberg, L. O., & Schedin‐Weiss, S. (2022) · Glycobiology · doi:10.1093/glycob/cwac009 · Cited by 20
The Hidden Role of Non-Canonical Amyloid β Isoforms in Alzheimer’s Disease
Busch, L., Eggert, S., Endres, K., & Bufe, B. (2022) · Cells · doi:10.3390/cells11213421 · Cited by 20
Casares, N., Alfaro, M., Cuadrado‐Tejedor, M., Lasarte-Cía, A., Navarro, F. C., Vivas, I., Espelosin, M., Cartas‐Cejudo, P., Fernández‐Irigoyen, J., Santamaría, E., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1130044 · Cited by 20
Ulaganathan, S., & Pitchaimani, A. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121918 · Cited by 23
Rodent Models of Alzheimer’s Disease: Past Misconceptions and Future Prospects
Collins, H. M., & Greenfield, S. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116222 · Cited by 21
Górska, A. M., Santos‐García, I., Eiriz, I., Brüning, T., Nyman, T. A., & Pahnke, J. (2024) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2024.110239 · Cited by 20
In Vivo Two Photon Imaging of Astrocytic Structure and Function in Alzheimer’s Disease
Kelly, P., Hudry, E., Hou, S. S., & Bacskai, B. J. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00219 · Cited by 20
Harper, M. M., Hedberg‐Buenz, A., Herlein, J. A., Abrahamson, E. E., Anderson, M. G., Kuehn, M. H., Kardon, R. H., Poolman, P., & Ikonomović, M. D. (2019) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-26353 · Cited by 20
Casein Kinase 2 dependent phosphorylation of eIF4B regulates BACE1 expression in Alzheimer’s disease
Bettegazzi, B., Monasor, L. S., Bellani, S., Codazzi, F., Restelli, L. M., Colombo, A. V., Deigendesch, N., Frank, S., Saito, T., Saido, T. C., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04062-3 · Cited by 20
Pinpointing the locus of GABAergic vulnerability in Alzheimer’s disease
Melgosa-Ecenarro, L., Doostdar, N., Radulescu, C. I., Jackson, J., & Barnes, S. J. (2022) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2022.06.017 · Cited by 20
Herzig, M. C., Paganetti, P., Staufenbiel, M., & Jucker, M. (2007) · Neurodegenerative Diseases · doi:10.1159/000101837 · Cited by 20
Self-citationUpregulation of β-amyloid precursor protein expression in glioblastoma multiforme
Culicchia, F., Cui, J.-G., Li, Y., & Lukiw, W. J. (2008) · Neuroreport · doi:10.1097/wnr.0b013e328302f139 · Cited by 20
Zhang, Z.-X., Zhao, R., Wang, D., & Wang, A.-N. (2016) · Experimental Gerontology · doi:10.1016/j.exger.2016.09.003 · Cited by 20
Biechele, G., Monasor, L. S., Wind-Mark, K., Blume, T., Parhizkar, S., Arzberger, T., Sacher, C., Beyer, L., Eckenweber, F., Gildehaus, F., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.261858 · Cited by 20
Self-citationIncrease in Tau Pathology in P290S Mapt Knock-In Mice Crossed with App NL-G-F Mice
Huang, M., Macdonald, J., Lavenir, I., Chen, R., Craxton, M., Slavik-Smith, E., Davies, S. W., & Goedert, M. (2022) · eneuro · doi:10.1523/eneuro.0247-22.2022 · Cited by 19
Quan, W., Luo, Q., Hao, W., Tomic, I., Furihata, T., Schulz‐Schaeffer, W., Menger, M. D., Fassbender, K. C., & Liu, Y. (2021) · Glia · doi:10.1002/glia.24007 · Cited by 20
Jia, Y., Wang, W., Han, N., Sun, H.-L., Dong, F., Song, Y., Feng, R.-F., & Wang, J.-H. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.02.076 · Cited by 19
VEGF controls microglial phagocytic response to amyloid-β
Gea, P. D., Benkeder, S., Bouvet, P., Aimard, M., Chounlamountri, N., Honnorat, J., Do, L.-D., & Meissirel, C. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1264402 · Cited by 19
Lu, X., Moeini, M., Li, B., Lu, Y., Damseh, R., Pouliot, P., Thorin, É., & Lesage, F. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01261 · Cited by 19
Vidal, C., & Li, Z. (2021) · Cells · doi:10.3390/cells10030546 · Cited by 20
PET Imaging in Preclinical Anti-Aβ Drug Development
Syvänen, S., Meier, S. R., Roshanbin, S., Xiong, M., Faresjö, R., Gustavsson, T., Bonvicini, G., Schlein, E., Aguilar, X., Julku, U. H., et al. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03277-z · Cited by 20
Calpain-2 Mediates MBNL2 Degradation and a Developmental RNA Processing Program in Neurodegeneration
Wang, L., Lin, C., Lin, Y.-M., Buée, L., Sergeant, N., Blum, D. L., Chern, Y., & Wang, G. (2022) · Journal of Neuroscience · doi:10.1523/jneurosci.2006-21.2022 · Cited by 19
Bruley-Rosset, M., Lui, G., Dansokho, C., Chaigneau, T., & Dorothée, G. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0317-5 · Cited by 19
Ovsepian, S. V., Blázquez‐Llorca, L., Valero-Freitag, S., Rodrigues, E. F., & Herms, J. W. (2016) · Cerebral Cortex · doi:10.1093/cercor/bhw267 · Cited by 19
Genomics: New Light on Alzheimer’s Disease Research
Jung, Y. J., Kim, Y. H., Bhalla, M., Lee, S. B., & Seo, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123771 · Cited by 19
Garad, M., Edelmann, E., & Leßmann, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031378 · Cited by 19
Tong, G., Izquierdo, P., & Raashid, R. A. (2017) · The Open Neurology Journal · doi:10.2174/1874205x01711010027 · Cited by 18
Ni, R. (2021) · Pharmaceuticals · doi:10.3390/ph14111179 · Cited by 18
Stress regulates Alzheimer’s disease progression via selective enrichment of CD8+ T cells
Feng, Y., Fan, J., Cheng, Y., Dai, Q., & Ma, S. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113313 · Cited by 19
Human stem cell transplantation models of Alzheimer’s disease
Ifediora, N., Canoll, P., & Hargus, G. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1354164 · Cited by 18
A novel NIR fluorescent probe for visualizing hydrogen sulfide in Alzheimer's disease
Hong, S., Gan, Y., Liu, D., Yu, T., Zhou, H., Li, H., Liu, F., & Yin, P. (2024) · The Analyst · doi:10.1039/d4an00819g · Cited by 18
Repression of telomere-associated genes by microglia activation in neuropsychiatric disease
Kronenberg, G., Uhlemann, R., Schöner, J., Wegner, S., Boujon, V., Deigendesch, N., Endres, M., & Gertz, K. R. (2016) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-016-0750-1 · Cited by 18
He, Z., Wang, M.-H., Zhao, Q., Li, X., Liu, P., Ren, B., Wu, C., Du, X., Li, N., & Liu, Q. (2020) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2020.111073 · Cited by 18
Rai, S. P., Krohn, M., & Pahnke, J. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200161 · Cited by 18
Kumar, V., Lee, J. D., Coulson, E. J., & Woodruff, T. M. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15119 · Cited by 18
Janssens, J., Hermans, B., Vandermeeren, M., Barale-Thomas, E., Borgers, M., Willems, R., Meulders, G., Wintmolders, C., den Bulck, D. V., Bottelbergs, A., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105365 · Cited by 18
Principles of brain aging: Status and challenges of modeling human molecular changes in mice
Kluever, V., & Fornasiero, E. F. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101465 · Cited by 18
Dromard, Y., Arango-Lievano, M., Borie, A. M., Dedin, M., Fontanaud, P., Torrent, J., Garabedian, M. J., Ginsberg, S. D., & Jeanneteau, F. D. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01396-7 · Cited by 18
Sinnige, T., Stroobants, K., Dobson, C. M., & Vendruscolo, M. (2020) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583520000025 · Cited by 18
Mănescu, M. D., Cătălin, B., Bâldea, I., Mateescu, V. O., Roşu, G. C., Boboc, I. K. Ş., Istrate-Ofiţeru, A.-M., Liliac, I. M., Streba, C. T., Kumar‐Singh, S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70164 · Cited by 17
Effects of Qi-Fu-Yin on aging of APP/PS1 transgenic mice by regulating the intestinal microbiome
Xiao, Q., Ye, T., Wang, X., Qi, D., & Cheng, X. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1048513 · Cited by 17
Optogenetic and chemogenetic approaches for modeling neurological disorders in vivo
Krut’, V. G., Kalinichenko, A. L., Maltsev, D. I., Jappy, D., Shevchenko, E. K., Podgorny, O. V., & Belousov, V. V. (2024) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2024.102600 · Cited by 17
Extracellular vesicles contribute to the beneficial effects of exercise training in APP/PS1 mice
Fuller, O. K., McLennan, E. D., Egan, C. L., Perera, N., Terry, L. V., Pyun, J., de Mendonca, M., Telles, G. D., Smeuninx, B., Burrows, E. L., et al. (2025) · iScience · doi:10.1016/j.isci.2025.111752 · Cited by 17
Vignon, A., Salvador-Prince, L., Lehmann, S., Perrier, V., & Torrent, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168769 · Cited by 17
Cope, Z. A., Murai, T., & Rizzo, S. J. S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.805063 · Cited by 18
Yang, B., He, M., Chen, X., Sun, M., Pan, T., Xu, X., Zhang, X., Gong, Q., Zhao, Y., Jin, Z., et al. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/1527159 · Cited by 17
Retracted
Metadata
- Authors
- Radde, R., Bolmont, T., Kaeser, S. A., Coomaraswamy, J., Lindau, D., Stoltze, L., Calhoun, M. E., Jäggi, F., Wolburg, H., Gengler, S., Haass, C., Ghetti, B., Czech, C., Hölscher, C., Mathews, P. M., & Jucker, M.
- Affiliations
- Hertie Institute for Clinical Brain Research (DE)
- University of Basel (CH)
- University of Tübingen (DE)
- University of Ulster (GB)
- Adolf-Butenandt-Institut für Physiologische Chemie, Physikalische Biochemie und Zellbiologie (DE)
- Indiana University School of Medicine (US)
- F. Hoffmann-La Roche AG (CH)
- New York University (US)
- Corresponding author
- Jucker, Mathias
- ORCID
- Venue
- The EMBO Reports
- Published
- 2006-08-11
- Volume
- 7
- Issue
- 9
- Pages
- 940-946
- ISSN
- 1469-221X (ISSN-L)
- 1469-3178
- PMC
- PMC1559665
- OpenAlex
- W2156788921
- Cited by
- 986
- References
- 32
- Citations by year
- 2026: 33 · 2025: 60 · 2024: 75 · 2023: 85 · 2022: 73 · 2021: 86 · 2020: 93 · 2019: 79 · 2018: 58 · 2017: 41 · 2016: 46 · 2015: 41 · 2014: 36 · 2013: 50 · 2012: 37
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- EMBO Reports (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Funders
- European Commission (LSHM-CT-2003-503330)
- Boehringer Ingelheim Stiftung
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- cerebral amyloidosis, amyloid-beta 42, amyloid angiopathy, tau hyperphosphorylation, gliosis, microglia, Alzheimer's disease model
- MeSH terms
- Animals, Cognition, Disease Models, Animal, Inflammation, Male, Membrane Proteins, Mice, Inbred C57BL, Mice, Transgenic, Neurons, Peptide Fragments, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Cerebral Amyloid Angiopathy, Neocortex, Mice, Presenilin-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
